• SELECT SITE CURRENCY
Select a currency for use throughout the site
DRG Insight: Hypertension (G7)
Decision Resources, Inc, June 2012, Pages: 54
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives.
The hypertension market, though mature and heavily genericized, offers significant opportunities for blood pressure (BP)-lowering drugs that can prevent the development of cardiovascular disease, cerebrovascular disease, or end-organ damage.
The best on-market single-agent therapies achieve only relatively modest levels of BP reduction, hence the increasing prominence of fixed-dose combination (FDC) drugs in the market. However, physicians value the ability to titrate drug therapy, and payers are increasingly rewarding innovation and novel modes of therapeutic action, which signals room for new antihypertensive agents.
For existing and emerging therapies alike, the high disease prevalence, ease of diagnosis, and recognized need to treat hypertension also translates to substantial sales potential, even for therapies that capture a small share of the market.
Current Market Landscape
Etiology & Pathophysiology
Select Drug Targets
Growth Drivers & Constraints
Country Specific Decision Trees
Comparison of Key Agents
Expert Insight on Prescribing Trends
Importance of Drug Attributes in Prescribing Decisions
Pricing & Reimbursement
Factors Influencing Pharmacy Director Tier Placement Decisions
Accessibility and Cost Hurdles
Important Endpoints in Prescribing Decisions
2010 and 2010 sales and Market Share